KELOWNA, British Columbia, April 19, 2017, MRPHF, /PRNewswire/ —
Marapharm (OTCQB: MRPHF) has been added (source: forbes.com) to the United States Marijuana Index (marijuanaindex.com). The North American Marijuana Index, composed from the United States Marijuana Index and the Canadian Marijuana Index, tracks the leading cannabis stocks listed on North American stock exchanges. The North American Marijuana Index level in April 2016 was 50 and in April 2017 the index level is 150, an increase of approximately 200%. In order for a company to be in the Index the criteria includes having a weighted average minimum market daily trading volume of $600,000.
A stock market index is a measurement of the value of a section of the stock market. It is computed from the prices of selected stocks. It is a tool used by investors and financial managers to describe the market and to compare the return of specific investments.
“Marapharm is pleased to be part of this important index which is the voice of credibility for the rapid development of the marijuana sector. We are executing on our plans, by bringing the Nevada facility into production, capitalizing on the real estate acquisition in Washington, have property and permits in California and will continue to look for additional opportunities for cultivation and production licenses and facilities in the United States. In addition, our investment in Veritas Pharma continues to provide synergy and our investment has more than doubled in value within 3 months,” Linda Sampson, Marapharm CEO.
ABOUT MARAPHARM VENTURES INC.
Construction photos and videos can be accessed through the Marapharm website. Marapharms common shares are publicly traded in Canada, under the ticker symbol “MDM” on the Canadian Securities Exchange, and in the United States, under the ticker symbol “MRPHF” on the OTCQB, and in Europe, under the ticker symbol “2M0” on the FSE.
Marapharm has 300,000 square feet of medical marijuana licenses for its land and facilities in WA and NV. About two and a half years ago, Marapharm applied in Canada to Health Canada for a MMPR (production and sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR.
Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (http://www.thecse.com), the OTC website (http://www.otcmarkets.com), and the SEDAR website (http://www.sedar.com) under the profile for Marapharm Ventures Inc.
STOCK EXCHANGES:
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
FORWARD – LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, ‘may”, “will”, “project”, “should”, ‘believe”, and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.
FOR FURTHER INFORMATION:
Linda Sampson
CEO
+1-778-583-4476
email – info@marapharm.com
SOURCE Marapharm Ventures Inc.
